| Schedule of Segment Reporting Information, by Segment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biopharmaceuticals |
|
Bioprocessing |
|
|
|
|
Three Months Ended March 31, 2022 (in thousands) |
|
iBio, Inc. |
|
iBio CDMO |
|
Eliminations |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues - external customers |
|
$ |
1,800 |
|
$ |
143 |
|
$ |
— |
|
$ |
1,943 |
Revenues - intersegment |
|
|
817 |
|
|
604 |
|
|
(1,421) |
|
|
— |
Cost of goods sold |
|
|
— |
|
|
48 |
|
|
— |
|
|
48 |
Gross profit |
|
|
2,617 |
|
|
699 |
|
|
(1,421) |
|
|
1,895 |
Research and development |
|
|
3,764 |
|
|
2,416 |
|
|
(629) |
|
|
5,551 |
General and administrative |
|
|
5,430 |
|
|
3,888 |
|
|
(792) |
|
|
8,526 |
Operating loss |
|
|
(6,577) |
|
|
(5,605) |
|
|
— |
|
|
(12,182) |
Interest expense |
|
|
— |
|
|
(250) |
|
|
— |
|
|
(250) |
Interest and other income |
|
|
40 |
|
|
2 |
|
|
— |
|
|
42 |
Consolidated net loss |
|
|
(6,538) |
|
|
(5,852) |
|
|
— |
|
|
(12,390) |
Total assets |
|
|
165,896 |
|
|
40,429 |
|
|
(90,955) |
|
|
115,370 |
Finance lease ROU assets |
|
|
— |
|
|
86 |
|
|
— |
|
|
86 |
Operating lease ROU assets |
|
|
3,209 |
|
|
1,942 |
|
|
— |
|
|
5,151 |
Fixed assets, net |
|
|
1,068 |
|
|
33,513 |
|
|
— |
|
|
34,581 |
Intangible assets, net |
|
|
4,919 |
|
|
— |
|
|
— |
|
|
4,919 |
Amortization of ROU assets |
|
|
— |
|
|
24 |
|
|
— |
|
|
24 |
Depreciation expense |
|
|
— |
|
|
709 |
|
|
— |
|
|
709 |
Amortization of intangible assets |
|
|
122 |
|
|
— |
|
|
— |
|
|
122 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biopharmaceuticals |
|
Bioprocessing |
|
|
|
|
Three Months Ended March 31, 2021 (in thousands) |
|
iBio, Inc. |
|
iBio CDMO |
|
Eliminations |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues - external customers |
|
$ |
700 |
|
$ |
65 |
|
$ |
— |
|
$ |
765 |
Revenues - intersegment |
|
|
191 |
|
|
688 |
|
|
(879) |
|
|
— |
Cost of goods sold |
|
|
229 |
|
|
264 |
|
|
— |
|
|
493 |
Gross profit |
|
|
662 |
|
|
489 |
|
|
(879) |
|
|
272 |
Research and development |
|
|
1,500 |
|
|
1,353 |
|
|
(691) |
|
|
2,162 |
General and administrative |
|
|
3,438 |
|
|
2,062 |
|
|
(187) |
|
|
5,313 |
Operating loss |
|
|
(4,276) |
|
|
(2,927) |
|
|
— |
|
|
(7,203) |
Interest expense |
|
|
— |
|
|
(612) |
|
|
— |
|
|
(612) |
Interest and other income |
|
|
153 |
|
|
— |
|
|
— |
|
|
153 |
Consolidated net loss |
|
|
(4,123) |
|
|
(3,539) |
|
|
— |
|
|
(7,662) |
Total assets |
|
|
165,096 |
|
|
35,123 |
|
|
(57,522) |
|
|
142,697 |
Finance lease ROU assets |
|
|
— |
|
|
26,380 |
|
|
— |
|
|
26,380 |
Fixed assets, net |
|
|
— |
|
|
6,407 |
|
|
— |
|
|
6,407 |
Intangible assets, net |
|
|
1,146 |
|
|
— |
|
|
— |
|
|
1,146 |
Amortization of ROU assets |
|
|
— |
|
|
406 |
|
|
— |
|
|
406 |
Depreciation expense |
|
|
— |
|
|
119 |
|
|
— |
|
|
119 |
Amortization of intangible assets |
|
|
73 |
|
|
— |
|
|
— |
|
|
73 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biopharmaceuticals |
|
Bioprocessing |
|
|
|
|
Nine Months Ended March 31, 2022 (in thousands) |
|
iBio, Inc. |
|
iBio CDMO |
|
Eliminations |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues - external customers |
|
$ |
1,884 |
|
$ |
438 |
|
$ |
— |
|
$ |
2,322 |
Revenues - intersegment |
|
|
993 |
|
|
1,489 |
|
|
(2,482) |
|
|
— |
Cost of goods sold |
|
|
— |
|
|
201 |
|
|
— |
|
|
201 |
Gross profit |
|
|
2,877 |
|
|
1,726 |
|
|
(2,482) |
|
|
2,121 |
Research and development |
|
|
7,498 |
|
|
5,432 |
|
|
(1,537) |
|
|
11,393 |
General and administrative |
|
|
13,746 |
|
|
10,721 |
|
|
(945) |
|
|
23,522 |
Operating loss |
|
|
(18,367) |
|
|
(14,427) |
|
|
— |
|
|
(32,794) |
Interest expense |
|
|
— |
|
|
(1,187) |
|
|
— |
|
|
(1,187) |
Forgiveness of note payable and accrued interest |
|
|
— |
|
|
607 |
|
|
— |
|
|
607 |
Interest and other income |
|
|
117 |
|
|
7 |
|
|
— |
|
|
124 |
Consolidated net loss |
|
|
(18,251) |
|
|
(14,999) |
|
|
— |
|
|
(33,250) |
Total assets |
|
|
165,896 |
|
|
40,429 |
|
|
(90,955) |
|
|
115,370 |
Finance lease ROU assets |
|
|
— |
|
|
86 |
|
|
— |
|
|
86 |
Operating lease ROU assets |
|
|
3,209 |
|
|
1,942 |
|
|
— |
|
|
5,151 |
Fixed assets, net |
|
|
1,068 |
|
|
33,513 |
|
|
— |
|
|
34,581 |
Intangible assets, net |
|
|
4,919 |
|
|
— |
|
|
— |
|
|
4,919 |
Amortization of ROU assets |
|
|
— |
|
|
587 |
|
|
— |
|
|
587 |
Depreciation expense |
|
|
— |
|
|
1,532 |
|
|
— |
|
|
1,532 |
Amortization of intangible assets |
|
|
333 |
|
|
— |
|
|
— |
|
|
333 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biopharmaceuticals |
|
Bioprocessing |
|
|
|
|
Nine Months Ended March 31, 2021 (in thousands) |
|
iBio, Inc. |
|
iBio CDMO |
|
Eliminations |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues - external customers |
|
$ |
1,097 |
|
$ |
783 |
|
$ |
— |
|
$ |
1,880 |
Revenues - intersegment |
|
|
667 |
|
|
1,186 |
|
|
(1,853) |
|
|
— |
Cost of goods sold |
|
|
425 |
|
|
850 |
|
|
— |
|
|
1,275 |
Gross profit |
|
|
1,339 |
|
|
1,119 |
|
|
(1,853) |
|
|
605 |
Research and development |
|
|
2,341 |
|
|
5,761 |
|
|
(1,210) |
|
|
6,892 |
General and administrative |
|
|
8,921 |
|
|
7,106 |
|
|
(642) |
|
|
15,385 |
Operating loss |
|
|
(9,923) |
|
|
(11,749) |
|
|
— |
|
|
(21,672) |
Interest expense |
|
|
— |
|
|
(1,841) |
|
|
— |
|
|
(1,841) |
Interest and other income |
|
|
185 |
|
|
1 |
|
|
— |
|
|
186 |
Consolidated net loss |
|
|
(9,738) |
|
|
(13,589) |
|
|
— |
|
|
(23,327) |
Total assets |
|
|
165,096 |
|
|
35,123 |
|
|
(57,522) |
|
|
142,697 |
Finance lease ROU assets |
|
|
— |
|
|
26,380 |
|
|
— |
|
|
26,380 |
Fixed assets, net |
|
|
— |
|
|
6,407 |
|
|
— |
|
|
6,407 |
Intangible assets, net |
|
|
1,146 |
|
|
— |
|
|
— |
|
|
1,146 |
Amortization of ROU assets |
|
|
— |
|
|
1,236 |
|
|
— |
|
|
1,236 |
Depreciation expense |
|
|
— |
|
|
330 |
|
|
— |
|
|
330 |
Amortization of intangible assets |
|
|
218 |
|
|
— |
|
|
— |
|
|
218 |
|